Health Canada approves biosimilar Niopeg (a pegylated form of filgrastim) in Canada.--Nora Pharma
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of Niopeg (a pegylated form of filgrastim) in Canada.
Niopeg is a Biosimilar comparable to the reference biologic drug Neulasta (pegfilgrastim). Niopeg is a long-acting form of recombinant human granulocyte colony-stimulating factor (r-HuG-CSF), or filgrastim. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Niopeg is available in a pre-filled syringe of 6 mg/0.6 mL.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins